Capsid-Incorporation of antigens into adenovirus capsid proteins for a vaccine approach

Molecular Pharmaceutics

Volumn 8, Issue 1, 2011, Pages 3-11

  Matthews, Qiana L ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus; Antigen; Capsid incorporation; Vaccine; Virus

Indexed keywords

ADENOVIRUS VECTOR; ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL PROTEIN; CIRCUMSPOROZOITE PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; EPI8 PROTEIN; GAG PROTEIN; HEXON PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LUCIFERASE; NEUTRALIZING ANTIBODY; OUTER MEMBRANE PROTEIN F; PENTON BASE; PROTECTIVE ANTIGEN; PROTEIN POLYPEPTIDE 4; PROTEIN VP1; PSEUDOMONAS VACCINE; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN; VIRUS FIBER PROTEIN; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS 5; AMINO ACID SEQUENCE; ANTHRAX; ANTIBODY RESPONSE; ANTIGEN CAPSID INCORPORATION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; BACILLUS ANTHRACIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ELECTRON MICROSCOPY; FRIEND LEUKEMIA VIRUS; GENE EXPRESSION; GENETIC MANIPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERVARIABLE REGION; IN VIVO GENE TRANSFER; INTERNALIZATION; MALARIA; MEMBRANE PERMEABILITY; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; RHINOVIRUS; SIGNAL TRANSDUCTION; TARGET CELL; TRANSGENE; VACCINATION; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS MORPHOLOGY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS; CAPSID; CAPSID PROTEINS; GENETIC VECTORS; HUMANS; VACCINES;

EID: 79952943423     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100214b     Document Type: Review

References (87)

1. Harari, A.; Bart, P. A.; Stohr, W.; Tapia, G.; Garcia, M.; Medjitna-Rais, E.; Burnet, S.; Cellerai, C.; Erlwein, O.; Barber, T.; Moog,C.; Liljestrom, P.; Wagner, R.; Wolf, H.; Kraehenbuhl, J. P.;Esteban, M.; Heeney, J.; Frachette, M. J.; Tartaglia, J.; McCormack,S.; Babiker, A.; Weber, J.; Pantaleo, G. An HIV-1 clade CDNA prime, NYVAC boost vaccine regimen induces reliable,polyfunctional, and long-lasting T cell responses. J. Exp. Med.2008, 205 (1), 63-77. (Pubitemid 351185716)
2. Jaoko, W.; Karita, E.; Kayitenkore, K.; Omosa-Manyonyi, G.;Allen, S.; Than, S.; Adams, E. M.; Graham, B. S.; Koup, R. A.;Bailer, R. T.; Smith, C.; Dally, L.; Farah, B.; Anzala, O.; Muvunyi,C. M.; Bizimana, J.; Tarragona-Fiol, T.; Bergin, P. J.; Hayes, P.;Ho, M.; Loughran, K.; Komaroff, W.; Stevens, G.; Thomson, H.;Boaz, M. J.; Cox, J. H.; Schmidt, C.; Gilmour, J.; Nabel, G. J.;Fast, P.; Bwayo, J. Safety and immunogenicity study of MulticladeHIV-1 adenoviral vector vaccine alone or as boost following amulticlade HIV-1 DNA vaccine in Africa. PLoS One 2010, 5 (9),e12873.
3. Li, S.; Locke, E.; Bruder, J.; Clarke, D.; Doolan, D. L.; Havenga,M. J.; Hill, A. V.; Liljestrom, P.; Monath, T. P.; Naim, H. Y.;Ockenhouse, C.; Tang, D. C.; Van Kampen, K. R.; Viret, J. F.;Zavala, F.; Dubovsky, F. Viral vectors for malaria vaccinedevelopment. Vaccine 2007, 25 (14), 2567-2574.
4. Smith, A. D.; Geisler, S. C.; Chen, A. A.; Resnick, D. A.; Roy,B. M.; Lewi, P. J.; Arnold, E.; Arnold, G. F. Human rhinovirustype 14:human immunodeficiency virus type 1 (HIV-1) V3 loopchimeras from a combinatorial library induce potent neutralizingantibody responses against HIV-1. J. Virol. 1998, 72 (1), 651-659. (Pubitemid 28048883)
5. Arnold, G. F.; Velasco, P. K.; Holmes, A. K.; Wrin, T.; Geisler,S. C.; Phung, P.; Tian, Y.; Resnick, D. A.; Ma, X.; Mariano, T. M.;Petropoulos, C. J.; Taylor, J. W.; Katinger, H.; Arnold, E. Broadneutralization of human immunodeficiency virus type 1 (HIV-1)elicited from human rhinoviruses that display the HIV-1 gp41ELDKWA epitope. J. Virol. 2009, 83 (10), 5087-5100.
6. Patterson, S.; Papagatsias, T.; Benlahrech, A. Use of adenovirusin vaccines for HIV. Handb. Exp. Pharmacol. 2009, 188, 275-293.
7. Bangari, D. S.; Mittal, S. K. Development of nonhuman adenovirusesas vaccine vectors. Vaccine 2006, 24 (7), 849-862. (Pubitemid 43185300)
8. Crotty, S.; Andino, R. Poliovirus vaccine strains as mucosalvaccine vectors and their potential use to develop an AIDSvaccine. AdV. Drug DeliVery ReV. 2004, 56 (6), 835-852. (Pubitemid 38520102)
9. Amara, R. R.; Villinger, F.; Altman, J. D.; Lydy, S. L.; O'Neil,S. P.; Staprans, S. I.; Montefiori, D. C.; Xu, Y.; Herndon, J. G.;Wyatt, L. S.; Candido, M. A.; Kozyr, N. L.; Earl, P. L.; Smith,J. M.; Ma, H. L.; Grimm, B. D.; Hulsey, M. L.; Miller, J.;McClure, H. M.; McNicholl, J. M.; Moss, B.; Robinson, H. L.Control of a mucosal challenge and prevention of AIDS by amultiprotein DNA/MVA vaccine. Science 2001, 292 (5514), 69-74. (Pubitemid 32289126)
10. Gherardi, M. M.; Esteban, M. Recombinant poxviruses as mucosalvaccine vectors. J. Gen. Virol. 2005, 86 (Part 11), 2925-2936.
11. Langley, W. A.; Bradley, K. C.; Li, Z. N.; Smith, M. E.; Schnell,M. J.; Steinhauer, D. A. Induction of neutralizing antibodyresponses to anthrax protective antigen by using influenza virusvectors: implications for disparate immune system primingpathways. J. Virol. 2010, 84 (16), 8300-8307.
12. Slobod, K. S.; Lockey, T. D.; Howlett, N.; Srinivas, R. V.;Rencher, S. D.; Freiden, P. J.; Doherty, P. C.; Hurwitz, J. L.Subcutaneous administration of a recombinant vaccinia virusvaccine expressing multiple envelopes of HIV-1. Eur. J. Clin.Microbiol. Infect. Dis. 2004, 23 (2), 106-110. (Pubitemid 38392137)
13. Journal Gene Therapy Worldwide Web site. www.wiley.co.uk/genetherapy/ clinical. Ref Type: Generic.
14. Kay, M. A.; Glorioso, J. C.; Naldini, L. Viral vectors for genetherapy: the art of turning infectious agents into vehicles oftherapeutics. Nat. Med. 2001, 7 (1), 33-40. (Pubitemid 32095639)
15. Barnett, B. G.; Crews, C. J.; Douglas, J. T. Targeted adenoviralvectors. Biochim. Biophys. Acta 2002, 1575 (13), 1-14. (Pubitemid 34521771)
16. Curiel, D. T. Strategies to adapt adenoviral vectors for targeteddelivery. Ann. N.Y. Acad. Sci. 1999, 886, 158-171. (Pubitemid 30042431)
17. Chirmule, N.; Propert, K.; Magosin, S.; Qian, Y.; Qian, R.; Wilson,J. Immune responses to adenovirus and adeno-associated virusin humans. Gene Ther. 1999, 6 (9), 1574-1583. (Pubitemid 29465516)
18. Kass-Eisler, A.; Falck-Pedersen, E.; Elfenbein, D. H.; Alvira, M.;Buttrick, P. M.; Leinwand, L. A. The impact of developmentalstage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1994, 1 (6), 395-402.
19. Kass-Eisler, A.; Leinwand, L.; Gall, J.; Bloom, B.; Falck-Pedersen,E. Circumventing the immune response to adenovirus-mediatedgene therapy. Gene Ther. 1996, 3 (2), 154-162.
20. Wohlfart, C. Neutralization of adenoviruses: kinetics, stoichiometry,and mechanisms. J. Virol. 1988, 62 (7), 2321-2328.
21. Schagen, F. H.; Ossevoort, M.; Toes, R. E.; Hoeben, R. C. Immuneresponses against adenoviral vectors and their transgene products:a review of strategies for evasion. Crit. Rev. Oncol. Hematol.2004, 50 (1), 51-70. (Pubitemid 38501617)
22. Shiratsuchi, T.; Rai, U.; Krause, A.; Worgall, S.; Tsuji, M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunityto adenovirus in mice. J. Clin. Invest 2010, 120 (10), 3688-3701.
23. Yang, Y.; Li, Q.; Ertl, H. C.; Wilson, J. M. Cellular and humoralimmune responses to viral antigens create barriers to lung-directedgene therapy with recombinant adenoviruses. J. Virol. 1995, 69(4), 2004-2015.
24. Jooss, K.; Chirmule, N. Immunity to adenovirus and adenoassociatedviral vectors: implications for gene therapy. Gene Ther.2003, 10 (11), 955-963. (Pubitemid 36722430)
25. Sette, A.; Fikes, J. Epitope-based vaccines: an update on epitopeidentification, vaccine design and delivery. Curr. Opin. Immunol.2003, 15 (4), 461-470. (Pubitemid 36934509)
26. Heath, W. R.; Carbone, F. R. Cross-presentation, dendritic cells,tolerance and immunity. Annu. ReV. Immunol. 2001, 19, 47-64. (Pubitemid 32368029)
27. Carbone, F. R.; Heath, W. R. Cross-priming: its beginnings.J. Immunol. 2010, 185 (3), 1353-1354.
28. Worgall, S.; Krause, A.; Rivara, M.; Hee, K. K.; Vintayen, E. V.;Hackett, N. R.; Roelvink, P. W.; Bruder, J. T.; Wickham, T. J.;Kovesdi, I.; Crystal, R. G. Protection against P. aeruginosa withan adenovirus vector containing an OprF epitope in the capsid.J. Clin. InVest. 2005, 115 (5), 1281-1289. (Pubitemid 40629047)
29. Krasnykh, V. N.; Mikheeva, G. V.; Douglas, J. T.; Curiel, D. T.Generation of recombinant adenovirus vectors with modified fibersfor altering viral tropism. J. Virol. 1996, 70 (10), 6839-6846. (Pubitemid 26307395)
30. Belousova, N.; Krendelchtchikova, V.; Curiel, D. T.; Krasnykh,V. Modulation of adenovirus vector tropism via incorporation ofpolypeptide ligands into the fiber protein. J. Virol. 2002, 76 (17),8621-8631. (Pubitemid 34864056)
31. Rux, J. J.; Burnett, R. M. Adenovirus structure. Hum. Gene Ther.2004, 15 (12), 1167-1176. (Pubitemid 40052430)
32. Nemerow, G. R.; Pache, L.; Reddy, V.; Stewart, P. L. Insightsinto adenovirus host cell interactions from structural studies.Virology 2009, 384 (2), 380-388.
33. van, O. J.; Burnett, R. M. Molecular composition of the adenovirustype 2 virion. J. Virol. 1985, 56 (2), 439-448. (Pubitemid 16192330)
34. Rux, J. J.; Kuser, P. R.; Burnett, R. M. Structural and phylogeneticanalysis of adenovirus hexons by use of high-resolution x-raycrystallographic, molecular modeling, and sequence-based methods.J. Virol. 2003, 77 (17), 9553-9566. (Pubitemid 37011050)
35. Crawford-Miksza, L.; Schnurr, D. P. Analysis of 15 adenovirushexon proteins reveals the location and structure of sevenhypervariable regions containing serotype-specific residues. J. Virol.1996, 70 (3), 1836-1844. (Pubitemid 26062947)
36. Vigne, E.; Mahfouz, I.; Dedieu, J. F.; Brie, A.; Perricaudet, M.;Yeh, P. RGD inclusion in the hexon monomer provides adenovirustype 5-based vectors with a fiber knob-independent pathway forinfection. J. Virol. 1999, 73 (6), 5156-5161. (Pubitemid 29246779)
37. Wu, H.; Han, T.; Belousova, N.; Krasnykh, V.; Kashentseva, E.;Dmitriev, I.; Kataram, M.; Mahasreshti, P. J.; Curiel, D. T.Identification of sites in adenovirus hexon for foreign peptideincorporation. J. Virol. 2005, 79 (6), 3382-3390. (Pubitemid 40327926)
38. McConnell, M. J.; Danthinne, X.; Imperiale, M. J. Characterizationof a permissive epitope insertion site in adenovirus hexon. J. Virol.2006, 80 (11), 5361-5370.
39. Worgall, S.; Krause, A.; Qiu, J.; Joh, J.; Hackett, N. R.; Crystal,R. G. Protective immunity to pseudomonas aeruginosa inducedwith a capsid-modified adenovirus expressing P. aeruginosa OprF.J. Virol. 2007, 81 (24), 13801-13808. (Pubitemid 350247873)
40. Matthews, Q. L.; Yang, P.; Wu, Q.; Belousova, N.; Rivera, A. A.;Stoff-Khalili, M. A.; Waehler, R.; Hsu, H. C.; Li, Z.; Li, J.;Mountz, J. D.; Wu, H.; Curiel, D. T. Optimization of capsidincorporatedantigens for a novel adenovirus vaccine approach.Virol. J. 2008, 5, 98.
41. Krause, A.; Joh, J. H.; Hackett, N. R.; Roelvink, P. W.; Bruder,J. T.; Wickham, T. J.; Kovesdi, I.; Crystal, R. G.; Worgall, S.Epitopes expressed in different adenovirus capsid proteins inducedifferent levels of epitope-specific immunity. J. Virol. 2006, 80(11), 5523-5530.
42. Wickham, T. J.; Mathias, P.; Cheresh, D. A.; Nemerow, G. R.Integrins alpha v beta 3 and alpha v beta 5 promote adenovirusinternalization but not virus attachment. Cell 1993, 73 (2), 309-319. (Pubitemid 23123309)
43. Wickham, T. J.; Filardo, E. J.; Cheresh, D. A.; Nemerow, G. R.Integrin alpha v beta 5 selectively promotes adenovirus mediatedcell membrane permeabilization. J. Cell Biol. 1994, 127 (1), 257-264.
44. Bai, M.; Campisi, L.; Freimuth, P. Vitronectin receptor antibodiesinhibit infection of HeLa and A549 cells by adenovirus type 12but not by adenovirus type 2. J. Virol. 1994, 68 (9), 5925-5932. (Pubitemid 24258610)
45. Bai, M.; Harfe, B.; Freimuth, P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base proteinabolish its cell-rounding activity and delay virus reproduction inflat cells. J. Virol. 1993, 67 (9), 5198-5205. (Pubitemid 23241350)
46. Mathias, P.; Wickham, T.; Moore, M.; Nemerow, G. Multipleadenovirus serotypes use alpha v integrins for infection. J. Virol.1994, 68 (10), 6811-6814. (Pubitemid 24294939)
47. Stewart, P. L.; Chiu, C. Y.; Huang, S.; Muir, T.; Zhao, Y.; Chait,B.; Mathias, P.; Nemerow, G. R. Cryo-EM visualization of anexposed RGD epitope on adenovirus that escapes antibodyneutralization. EMBO J. 1997, 16 (6), 1189-1198. (Pubitemid 27136086)
48. Chiu, C. Y.; Mathias, P.; Nemerow, G. R.; Stewart, P. L. Structureof adenovirus complexed with its internalization receptor, alphavbeta5integrin. J. Virol. 1999, 73 (8), 6759-6768. (Pubitemid 29327859)
49. Hong, S. S.; Habib, N. A.; Franqueville, L.; Jensen, S.; Boulanger,P. A. Identification of adenovirus (ad) penton base neutralizingepitopes by use of sera from patients who had received conditionallyreplicative ad (addl1520) for treatment of liver tumors.J. Virol. 2003, 77 (19), 10366-10375. (Pubitemid 37129680)
50. Nakano, M. Y.; Boucke, K.; Suomalainen, M.; Stidwill, R. P.;Greber, U. F. The first step of adenovirus type 2 disassemblyoccurs at the cell surface, independently of endocytosis and escapeto the cytosol. J. Virol. 2000, 74 (15), 7085-7095. (Pubitemid 30470693)
51. Durmort, C.; Stehlin, C.; Schoehn, G.; Mitraki, A.; Drouet, E.;Cusack, S.; Burmeister, W. P. Structure of the fiber head of Ad3,a non-CAR-binding serotype of adenovirus. Virology 2001, 285(2), 302-312. (Pubitemid 32641891)
52. Xia, D.; Henry, L. J.; Gerard, R. D.; Deisenhofer, J. Crystalstructure of the receptor-binding domain of adenovirus type 5 fiberprotein at 1.7 A resolution. Structure 1994, 2 (12), 1259-1270. (Pubitemid 124001323)
53. van Raaij, M. J.; Louis, N.; Chroboczek, J.; Cusack, S. Structureof the human adenovirus serotype 2 fiber head domain at 1.5 Aresolution. Virology 1999, 262 (2), 333-343. (Pubitemid 29474296)
54. Bewley, M. C.; Springer, K.; Zhang, Y. B.; Freimuth, P.; Flanagan,J. M. Structural analysis of the mechanism of adenovirus bindingto its human cellular receptor, CAR. Science 1999, 286 (5444),1579-1583.
55. Signas, C.; Akusjarvi, G.; Pettersson, U. Adenovirus 3 fiberpolypeptide gene: implications for the structure of the fiber protein.J. Virol. 1985, 53 (2), 672-678. (Pubitemid 15157375)
56. Green, N. M.; Wrigley, N. G.; Russell, W. C.; Martin, S. R.;McLachlan, A. D. Evidence for a repeating cross-beta sheetstructure in the adenovirus fibre. EMBO J. 1983, 2 (8), 1357-1365.
57. Jerry, L. B.; Hui, L.; Jesus, G.; Igor, D.; Victor, K.; Christy, A. R.;Denise, R. S.; Ronald, D. A.; David, T. C.; Theresa, V. S. Usinga Tropism-Modified Adenoviral Vector to Circumvent InhibitoryFactors in Ascites Fluid. Hum. Gene Ther. 2000, 11 (12), 1657-1669.
58. Michael, S. I.; Hong, J. S.; Curiel, D. T.; Engler, J. A. Additionof a short peptide ligand to the adenovirus fiber protein. GeneTher. 1995, 2 (9), 660-668.
59. Wickham, T. J.; Tzeng, E.; Shears, L. L.; Roelvink, P. W.; Li,Y.; Lee, G. M.; Brough, D. E.; Lizonova, A.; Kovesdi, I. Increasedin vitro and in vivo gene transfer by adenovirus vectors containingchimeric fiber proteins. J. Virol. 1997, 71 (11), 8221-8229. (Pubitemid 27446397)
60. Krasnykh, V.; Dmitriev, I.; Mikheeva, G.; Miller, C. R.; Belousova,N.; Curiel, D. T. Characterization of an adenovirus vectorcontaining a heterologous peptide epitope in the HI loop of thefiber knob. J. Virol. 1998, 72 (3), 1844-1852. (Pubitemid 28100735)
61. van, O. J.; Smith, P. R.; Mohraz, M.; Burnett, R. M. Interpretationof electron micrographs of adenovirus hexon arrays using acrystallographic molecular model. J. Ultrastruct. Mol. Struct. Res.1986, 96 (13), 77-90.
62. Dmitriev, I. P.; Kashentseva, E. A.; Curiel, D. T. Engineering ofadenovirus vectors containing heterologous peptide sequences in the Cterminus of capsid protein IX. J. Virol. 2002, 76 (14), 6893-6899. (Pubitemid 41246204)
63. Parks, R. J. Adenovirus protein IX: a new look at an old protein.Mol. Ther. 2005, 11 (1), 19-25. (Pubitemid 40011995)
64. Meulenbroek, R. A.; Sargent, K. L.; Lunde, J.; Jasmin, B. J.; Parks,R. J. Use of adenovirus protein IX (pIX) to display largepolypeptides on the virion-generation of fluorescent virus throughthe incorporation of pIX-GFP. Mol. Ther. 2004, 9 (4), 617-624. (Pubitemid 38578812)
65. Le, L. P.; Everts, M.; Dmitriev, I. P.; Davydova, J. G.; Yamamoto,M.; Curiel, D. T. Fluorescently labeled adenovirus with pIX-EGFPfor vector detection. Mol. Imaging 2004, 3 (2), 105-116.
66. Li, J.; Le, L.; Sibley, D. A.; Mathis, J. M.; Curiel, D. T. Geneticincorporation of HSV-1 thymidine kinase into the adenovirusprotein IX for functional display on the virion. Virology 2005,338 (2), 247-258. (Pubitemid 41019191)
67. Matthews, Q. L.; Sibley, D. A.; Wu, H.; Li, J.; Stoff-Khalili, M. A.;Waehler, R.; Mathis, J. M.; Curiel, D. T. Genetic incorporationof a herpes simplex virus type 1 thymidine kinase and fireflyluciferase fusion into the adenovirus protein IX for functionaldisplay on the virion. Mol. Imaging 2006, 5 (4), 510-519. (Pubitemid 46142824)
68. Li, J.; Fatima, A.; Komarova, S.; Ugai, H.; Uprety, P.; Roth, J. C.;Wang, M.; Oster, R. A.; Curiel, D. T.; Matthews, Q. L. Evaluationof adenovirus capsid labeling versus transgene expression. Virol.J. 2010, 7, 21.
69. Kimball, K. J.; Rivera, A. A.; Zinn, K. R.; Icyuz, M.; Saini, V.;Li, J.; Zhu, Z. B.; Siegal, G. P.; Douglas, J. T.; Curiel, D. T.;Alvarez, R. D.; Borovjagin, A. V. Novel infectivity-enhancedoncolytic adenovirus with a capsid-incorporated dual-imagingmoiety for monitoring virotherapy in ovarian cancer. Mol. Imaging2009, 8 (5), 264-277.
70. Lopez, M.; Matthews, Q.; Curiel, D.; Borovjagin, A. Imaging inVector Development. In Molecular Imaging: Principles andPractice; Weissleder, Gambhir, Ross, Rehemtulla, eds.; BCDecker Inc.: 2010.
71. Borovjagin, A. V.; McNally, L. R.; Wang, M.; Curiel, D. T.;MacDougall, M. J.; Zinn, K. R. Noninvasive monitoring ofmRFP1- and mCherry-labeled oncolytic adenoviruses in anorthotopic breast cancer model by spectral imaging. Mol. Imaging2010, 9 (2), 59-75.
72. de Vrij, J.; Uil, T. G.; van den Hengel, S. K.; Cramer, S. J.;Koppers-Lalic, D.; Verweij, M. C.; Wiertz, E. J.; Vellinga, J.;Willemsen, R. A.; Hoeben, R. C. Adenovirus targeting to HLAA1/MAGE-A1-positive tumor cells by fusing a single-chain T-cellreceptor with minor capsid protein IX. Gene Ther. 2008, 15 (13),978-989. (Pubitemid 351865754)
73. Campos, S. K.; Parrott, M. B.; Barry, M. A. Avidin-based targetingand purification of a protein IX-modified, metabolically biotinylatedadenoviral vector. Mol. Ther. 2004, 9 (6), 942-954. (Pubitemid 38878139)
74. Crompton, J.; Toogood, C. I.; Wallis, N.; Hay, R. T. Expressionof a foreign epitope on the surface of the adenovirus hexon. J. Gen.Virol. 1994, 75 (Part 1), 133-139. (Pubitemid 24033989)
75. Garau, J.; Gomez, L. Pseudomonas aeruginosa pneumonia. Curr.Opin. Infect. Dis. 2003, 16 (2), 135-143. (Pubitemid 36521026)
76. Okada, N.; Saito, T.; Masunaga, Y.; Tsukada, Y.; Nakagawa, S.;Mizuguchi, H.; Mori, K.; Okada, Y.; Fujita, T.; Hayakawa, T.;Mayumi, T.; Yamamoto, A. Efficient antigen gene transductionusing Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiateantitumor vaccine efficacy and maturation of murine dendriticcells. Cancer Res. 2001, 61 (21), 7913-7919. (Pubitemid 33050987)
77. Worgall, S.; Busch, A.; Rivara, M.; Bonnyay, D.; Leopold, P. L.;Merritt, R.; Hackett, N. R.; Rovelink, P. W.; Bruder, J. T.;Wickham, T. J.; Kovesdi, I.; Crystal, R. G. Modification to thecapsid of the adenovirus vector that enhances dendritic cellinfection and transgene-specific cellular immune responses. J. Virol.2004, 78 (5), 2572-2580. (Pubitemid 38228952)
78. Dixon, T. C.; Meselson, M.; Guillemin, J.; Hanna, P. C. Anthrax.N. Engl. J. Med. 1999, 341 (11), 815-826. (Pubitemid 29420478)
79. Friend, C. Cell-free transmission in adult Swiss mice of a disease havingthe character of a leukemia. J. Exp. Med. 1957, 105 (4),307-318.
80. Bayer, W.; Tenbusch, M.; Lietz, R.; Johrden, L.; Schimmer, S.;Überla, K.; Dittmer, U.; Wildner, O. Vaccination with anAdenoviral Vector That Encodes and Displays a RetroviralAntigen Induces Improved Neutralizing Antibody and CD4+T-Cell Responses and Confers Enhanced Protection. J. Virol. 2010,84 (4), 19671976.
81. Dittmer, U.; Brooks, D. M.; Hasenkrug, K. J. Characterization ofa live-attenuated retroviral vaccine demonstrates protection viaimmune mechanisms. J. Virol. 1998, 72 (8), 6554-6558. (Pubitemid 28323970)
82. Fabry, C. M.; Rosa-Calatrava, M.; Conway, J. F.; Zubieta, C.;Cusack, S.; Ruigrok, R. W.; Schoehn, G. A quasi-atomic modelof human adenovirus type 5 capsid. EMBO J. 2005, 24 (9), 1645-1654. (Pubitemid 40704975)
83. Boyer, J. L.; Sofer-Podesta, C.; Ang, J.; Hackett, N. R.; Chiuchiolo,M. J.; Senina, S.; Perlin, D.; Crystal, R. G. ProtectiveImmunity against a Lethal Respiratory Yersinia pestis ChallengeInduced by V Antigen or the F1 Capsular Antigen Incorporatedinto Adenovirus Capsid. Hum. Gene Ther. 2010, 21 (7), 891-901.
84. Abe, S.; Okuda, K.; Ura, T.; Kondo, A.; Yoshida, A.; Yoshizaki,S.; Mizuguchi, H.; Klinman, D.; Shimada, M. Adenovirus type 5with modified hexons induces robust transgene-specific immuneresponses in mice with pre-existing immunity against adenovirustype 5. J. Gene Med. 2009, 11 (7), 570-579.
85. Matthews, Q. L.; Fatima, A.; Tang, Y.; Perry, B. A.; Tsuruta, Y.;Komarova, S.; Timares, L.; Zhao, C.; Makarova, N.; Borovjagin,A. V.; Stewart, P. L.; Wu, H.; Blackwell, J. L.; Curiel, D. T.HIV antigen incorporation within adenovirus hexon hypervariable2 for a novel HIV vaccine approach. PLoS One 2010, 5 (7),e11815.
86. Tang, Y.; Le, L. P.; Matthews, Q. L.; Han, T.; Wu, H.; Curiel,D. T. Derivation of a triple mosaic adenovirus based on modificationof the minor capsid protein IX. Virology 2008, 377 (2), 391-400. (Pubitemid 351833111)
87. Smith, A. D.; Resnick, D. A.; Zhang, A.; Geisler, S. C.; Arnold,E.; Arnold, G. F. Use of random systematic mutagenesis togenerate viable human rhinovirus 14 chimeras displaying humanimmunodeficiency virus type 1 V3 loop sequences. J. Virol. 1994,68 (1), 575-579.